Chronic inflammatory demyelinating polyneuropathy (CIDP) - Pipeline Insight, 2021

Publisher Name :
Date: 10-Feb-2021
No. of pages: 60
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "Chronic inflammatory demyelinating polyneuropathy (CIDP) - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

Chronic inflammatory demyelinating polyneuropathy (CIDP) Understanding

Chronic inflammatory demyelinating polyneuropathy (CIDP): Overview

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder which is characterized by inflammation of nerve roots and peripheral nerves in conjunction with destruction of myelin sheath of the nerve fibers. Loss or damage of myelin sheath can slowdown or block the nerve signals. CIDP is an auto-immune disorder with a very low prevalence of around 5-7 cases per 100,000 individuals. Males are more likely to get affected by CIDP as compared to females. At times, diagnosing CIDP can be very difficult. However, muscle weakness for more than two months along with symmetric proximal and distal weakness with reduced or absent tendon reflexes are highly suggestive of CIDP. There are various effective treatments available for CIDP which primarily consist of glucocorticoids (steroids) like prednisone, some immunosuppressive drugs, intravenous immunoglobulin, and plasma exchange.

"Chronic inflammatory demyelinating polyneuropathy (CIDP) - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline landscape is provided which includes the disease overview and Chronic inflammatory demyelinating polyneuropathy (CIDP) treatment guidelines. The assessment part of the report embraces, in depth Chronic inflammatory demyelinating polyneuropathy (CIDP) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic inflammatory demyelinating polyneuropathy (CIDP) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Chronic inflammatory demyelinating polyneuropathy (CIDP) R&D. The therapies under development are focused on novel approaches to treat/improve Chronic inflammatory demyelinating polyneuropathy (CIDP).

Chronic inflammatory demyelinating polyneuropathy (CIDP) Emerging Drugs Chapters

This segment of the Chronic inflammatory demyelinating polyneuropathy (CIDP) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic inflammatory demyelinating polyneuropathy (CIDP) Emerging Drugs

- HYQVIA: Takeda Pharmaceuticals

Takeda's lead drug candidate, HYQVIA, is a solution for subcutaneous administration. The drug is being developed for chronic inflammatory demyelinating polyneuropathy disorder. The drug has demonstrated good efficacy and tolerability. It has also been designated with orphan drug status for CIPD. It act as an immunomodulant that reacts with the receptor of targeted cells to up-regulate or down-regulate immune response.

- Rozanolixizumab: UCB Biopharma

UCB Biopharma's "novel" drug molecule Rozanolixizumab is currently being evaluated for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). The drug is a neonatal Fc receptor antagonist which belong to the class of anti-inflammatories as well as monoclonal antibodies. Rozanolixizumab works by binding with high-affinity to human neonatal Fc receptor (FcRn), selectively inhibiting IgG rescue and recycling.

Further product details are provided in the report……..

Chronic inflammatory demyelinating polyneuropathy (CIDP): Therapeutic Assessment

This segment of the report provides insights about the different Chronic inflammatory demyelinating polyneuropathy (CIDP) drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players in Chronic inflammatory demyelinating polyneuropathy (CIDP)

There are approx. 10+ key companies which are developing the therapies for Chronic inflammatory demyelinating polyneuropathy (CIDP). The companies which have their Chronic inflammatory demyelinating polyneuropathy (CIDP) drug candidates in the most advanced stage, i.e. phase III include, Takeda Pharmaceuticals.

- Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

- Late stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

Route of Administration

Chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Oral

- Parenteral

- intravitreal

- Subretinal

- Topical.

- Molecule Type

Products have been categorized under various Molecule types such as

- Monoclonal Antibody

- Peptides

- Polymer

- Small molecule

- Gene therapy

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic inflammatory demyelinating polyneuropathy (CIDP): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic inflammatory demyelinating polyneuropathy (CIDP) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic inflammatory demyelinating polyneuropathy (CIDP) drugs.

Chronic inflammatory demyelinating polyneuropathy (CIDP) Report Insights

- Chronic inflammatory demyelinating polyneuropathy (CIDP) Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Chronic inflammatory demyelinating polyneuropathy (CIDP) Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Chronic inflammatory demyelinating polyneuropathy (CIDP) drugs?

- How many Chronic inflammatory demyelinating polyneuropathy (CIDP) drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic inflammatory demyelinating polyneuropathy (CIDP)?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic inflammatory demyelinating polyneuropathy (CIDP) therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for Chronic inflammatory demyelinating polyneuropathy (CIDP) and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- Takeda Pharmaceuticals

- UCB Biopharma

- LFB Biotechnologies

- Argenx

- Octapharma

Key Products

- HYQVIA

- Rozanolixizumab

- I10E

- Efgartigimod

- NewGam

Chronic inflammatory demyelinating polyneuropathy (CIDP) - Pipeline Insight, 2021

Table of Contents

Introduction
Executive Summary
Chronic inflammatory demyelinating polyneuropathy (CIDP): Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Chronic inflammatory demyelinating polyneuropathy (CIDP) - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
• Chronic inflammatory demyelinating polyneuropathy (CIDP) companies' collaborations, Licensing, Acquisition -Deal Value Trends
Chronic inflammatory demyelinating polyneuropathy (CIDP) Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
HYQVIA: Takeda Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Rozanolixizumab: UCB Biopharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Chronic inflammatory demyelinating polyneuropathy (CIDP) Key Companies
Chronic inflammatory demyelinating polyneuropathy (CIDP) Key Products
Chronic inflammatory demyelinating polyneuropathy (CIDP)- Unmet Needs
Chronic inflammatory demyelinating polyneuropathy (CIDP)- Market Drivers and Barriers
Chronic inflammatory demyelinating polyneuropathy (CIDP)- Future Perspectives and Conclusion
Chronic inflammatory demyelinating polyneuropathy (CIDP) Analyst Views
Chronic inflammatory demyelinating polyneuropathy (CIDP) Key Companies
Appendix

List of Tables

Table 1 Total Products for Chronic inflammatory demyelinating polyneuropathy (CIDP)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures

Figure 1 Total Products for Chronic inflammatory demyelinating polyneuropathy (CIDP)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global Autism Spectrum Disorder Market Growth (Status and Outlook) 2021-2026
    Published: 17-Mar-2021        Price: US 3660 Onwards        Pages: 117
    According to this latest study, the 2021 growth of Autism Spectrum Disorder will have significant change from previous year. By the most conservative estimates of global Autism Spectrum Disorder market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 384400 million in 2020. Over the next five years the Autism Spectrum Disorder market will register a 17.9% CAGR in terms of revenue, the global market size will reach US$ 743920 million by 2026. ......
  • Global Gabapentin Market Growth 2021-2026
    Published: 16-Mar-2021        Price: US 3660 Onwards        Pages: 159
    According to this latest study, the 2021 growth of Gabapentin will have significant change from previous year. By the most conservative estimates of global Gabapentin market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 1482.5 million in 2020. Over the next five years the Gabapentin market will register a 1.9% CAGR in terms of revenue, the global market size will reach US$ 1596.4 million by 2026. This report presents a comprehensi......
  • Global Restless Legs Syndrome Market Research Report with Opportunities and Strategies to Boost Growth- COVID-19 Impact and Recovery
    Published: 16-Mar-2021        Price: US 3500 Onwards        Pages: 116
    Based on the Restless Legs Syndrome market development status, competitive landscape and development model in different regions of the world, this report is dedicated to providing niche markets, potential risks and comprehensive competitive strategy analysis in different fields. From the competitive advantages of different types of products and services, the development opportunities and consumption characteristics and structure analysis of the downstream application fields are all analy......
  • Global Gabapentin Market Research Report 2021
    Published: 17-Feb-2021        Price: US 2900 Onwards        Pages: 120
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Capsule - Tablet Segment by Application - Epilepsy - Neuropathic Pain - Restle......
  • Global Gabapentin Market Analysis 2016-2020 and Forecast 2021-2026
    Published: 13-Feb-2021        Price: US 2980 Onwards        Pages: 85
    Snapshot Gabapentin is an anti-epileptic medication, also called an anticonvulsant. It affects chemicals and nerves in the body that are involved in the cause of seizures and some types of pain. The global Gabapentin market size is estimated at xxx million USD with a CAGR xx% from 2016-2020 and is expected to reach xxx Million USD in 2021 with a CAGR xx% from 2021 to 2026. The report begins from overview of Industry Chain structure, and describes industry environment, then ana......
  • Global Biopolar Disorder Therapeutics Market Research Report 2021
    Published: 10-Feb-2021        Price: US 2900 Onwards        Pages: 92
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Mood Stabilizers - Antipsychotic Drugs - Antidepressant Drugs - Others Segment by App......
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) - Pipeline Insight, 2021
    Published: 10-Feb-2021        Price: US 1500 Onwards        Pages: 60
    DelveInsight's, "Chronic inflammatory demyelinating polyneuropathy (CIDP) - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pi......
  • Chronic Traumatic Encephalopathy - Pipeline Insight, 2021
    Published: 10-Feb-2021        Price: US 1500 Onwards        Pages: 60
    DelveInsight's, "Chronic Traumatic Encephalopathy - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Chronic traumatic encephalopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geogra......
  • Small Fiber Neuropathy - Pipeline Insight, 2021
    Published: 10-Feb-2021        Price: US 1500 Onwards        Pages: 60
    DelveInsight's, "Small Fiber Neuropathy - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Small Fiber Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered - ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs